Factors Affecting the Price of Krazati

Krazati (adagrasib), a KRAS G12C inhibitor for advanced cancers, has a price shaped by key factors.

Factors Affecting the Price of Krazati

High R&D costs, from developing this targeted therapy to extensive clinical trials for KRAS-mutated tumors like non-small cell lung cancer, drive pricing. Mirati Therapeutics’ patent exclusivity allows premium rates without generic competition. Production complexities, including specialized biologic manufacturing and strict quality control, add to expenses. Market demand for therapies addressing previously undruggable KRAS mutations and regional healthcare policies (e.g., insurance coverage) further influence patient costs.

Related Columns

Adagrasib(Krazati)

Locally advanced or metastatic NSCLC harboring KRAS G12C mutation who have...

WeChat Scan
Free Inquiry

What Are the Purchase Channels for Adagrasib?

Adagrasib is an innovative KRASG12C-targeted inhibitor that has shown promising efficacy in the treatment of non-small cell lung cancer and colorectal cancer.What Are the Purchase Channels for Adagras...

How much is Adagrasib?

Adagrasib is a targeted therapy for KRAS G12C mutations, which has attracted much attention in the field of non-small cell lung cancer in recent years. This article will systematically analyze the cor...

Where to buy genuine adagrasib

Adagrasib, also known as adagrasib, is a specific oral inhibitor targeting KRAS G12C mutant. It is not currently on the market. The following is an introduction to where to buy genuine adagrasib, its ...